Welcome to our dedicated page for 22nd Century Group news (Ticker: XXII), a resource for investors and traders seeking the latest updates and insights on 22nd Century Group stock.
22nd Century Group, Inc. (NASDAQ: XXII) is a pioneering agricultural biotechnology company based in the United States. The company specializes in reducing the harms associated with smoking through advanced plant science technologies. 22nd Century leverages proprietary technology to precisely control the levels of nicotine in tobacco plants, making them significantly lower or higher through genetic engineering and selective breeding.
22nd Century operates primarily in the tobacco sector, commercializing its proprietary very low nicotine content (VLNC) tobacco plants and cigarette products. These products include reduced nicotine tobacco cigarettes marketed under the brand VLN®, which have up to 97% less nicotine than traditional cigarettes. VLN® received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette in December 2021, underscoring its breakthrough in the industry.
The company also has a significant footprint in the cannabis sector, applying its technology to control cannabinoid levels in cannabis plants, aiming to optimize health and wellness benefits. The company's wholly-owned subsidiaries, Goodrich Tobacco Company and Hercules Pharmaceuticals, focus on premium tobacco products and smoking cessation aids, respectively.
Recent strategic moves include restructuring to streamline operations and improve financial performance. The company has reduced cash use from $15 million a quarter to under $4 million projected for the first quarter of 2024. Recent business highlights feature new contract manufacturing agreements and expanded product lines, such as the Pinnacle brand cigarettes and cigarillos. These efforts are expected to propel 22nd Century towards cash-positive operations by Q1 2025.
Financially, the company has taken steps to bolster its balance sheet, announcing multiple equity transactions to reduce long-term and short-term debt. As of December 31, 2023, the company held $2.1 million in cash, with subsequent capital infusions improving liquidity. Revenue is majorly derived from its tobacco segment, with research cigarettes sold under the SPECTRUM brand adding to commercial activities.
For investors, 22nd Century's commitment to innovation in plant biotechnology presents a compelling case for growth. The company continues to host quarterly earnings calls, with the latest results showing promising advances in both financial metrics and strategic goals. Learn more at xxiicentury.com
22nd Century Group (Nasdaq: XXII), an innovative biotechnology firm focused on plant sciences, announced its participation in various virtual investor conferences in September and October 2021. Key events include a fireside chat at the BTIG Cannabis Conference on September 29, a presentation at the LD Micro Main Event on October 12, and participation in the Dawson James Small Cap Conference on October 21. CEO James A. Mish will outline business development efforts, including plans for commercialization of VLN® reduced nicotine cigarettes and proprietary hemp/cannabis initiatives.
22nd Century Group (Nasdaq: XXII) announced its entry into the global specialty hops market, marking its third plant franchise, as detailed in a shareholder update from CEO James A. Mish. The company is establishing a new subsidiary in the Netherlands to capitalize on opportunities in this market, which has an estimated $1.3 trillion total addressable market. The company aims to use its expertise in plant science and advanced breeding technologies to accelerate the commercialization of proprietary hop plants, enhancing products in the brewing and nutraceutical industries.
22nd Century Group, Inc. (Nasdaq: XXII) has appointed Anthony Johnson to its Board of Directors, enhancing its expertise in biotechnology and commercialization strategies. Johnson, a notable leader in life sciences, brings extensive experience from his roles at Kodikaz Therapeutic Solutions and Empire Genomics. His diverse background, spanning international markets, is expected to bolster 22nd Century's initiatives in tobacco harm reduction and cannabis research. This strategic move aims to drive business development and value creation as the company works on innovative plant-based technologies.
22nd Century Group (Nasdaq: XXII), a leader in plant-based biotechnology, announced CEO James A. Mish will present at the SNN Network Summer Virtual Event on August 19, 2021, at 2:30 p.m. ET. The event will be accessible via a live webcast on the company’s Investor Relations website. Attendees can request one-on-one meetings with company representatives through the conference website or by contacting investor relations directly. The company focuses on reducing tobacco harm through reduced nicotine content cigarettes and enhancing hemp/cannabis strains for better cannabinoid profiles.
On August 16, 2021, 22nd Century Group (Nasdaq: XXII) celebrated its transfer from the NYSE American to the Nasdaq Capital Market by ringing the Nasdaq Closing Bell. This move reflects the company's strategic growth in the biotechnology sector, focusing on tobacco harm reduction and hemp/cannabis research. CEO James A. Mish indicated the uplisting enhances the company's visibility and supports long-term revenue growth. The common stock will continue trading under the XXII ticker symbol.
22nd Century Group (NYSE American: XXII) announced its common stock uplisting to the Nasdaq Capital Market, effective August 16, 2021. This strategic move aims to enhance visibility to institutional investors and expand exposure to the hemp/cannabis sector as the industry progresses. CEO James A. Mish emphasized the alignment with high-achieving companies, reinforcing their commitment to reducing smoking harm through reduced nicotine tobacco products, and advancing innovations in hemp/cannabis technology.
22nd Century Group (XXII) reported record second quarter net sales of $8.4 million, up over 30% from last year. The company holds a strong cash position of $62.3 million as of June 30, 2021, enhancing its readiness for the upcoming VLN® tobacco product launch and the international expansion planned for early 2022. The FDA's review of the Modified Risk Tobacco Product (MRTP) application is progressing, with no outstanding inquiries. First revenue from its hemp/cannabis franchise is expected in Q3 2021.
22nd Century Group (NYSE American: XXII) has announced a new partnership with a leading tobacco exporter, prompting increased investment in production and testing equipment, as well as staff hiring at its North Carolina facility. The company is positioning itself for the global launch of its VLN® reduced nicotine cigarettes, anticipating FDA authorization soon. Improved testing capabilities are expected to lower production costs significantly. The firm is also seeking to expand its distribution channels.
22nd Century Group, with ticker XXII, announced a live webcast on August 5, 2021, at 10:00 AM ET to discuss its second quarter 2021 results. The company will release its results on the same day at 6:00 AM ET. CEO James A. Mish, COO Michael Zercher, and CFO John Franzino will present the results and discuss growth opportunities in the $1.3 trillion addressable market. An interactive Q&A session will follow. Interested parties can access the webcast via the company’s Investor Relations website. 22nd Century focuses on reducing tobacco harm and advancing hemp/cannabis research.
22nd Century Group (NYSE American: XXII) has established strategic partnerships with leading commercial-scale plant breeders, which will enhance its capabilities in alkaloid-based plant breeding and cultivation. These collaborations are aimed at optimizing development cycles from 7-10 years to just 2 years, crucial for meeting the growing demand for stable hemp/cannabis genetics. The company anticipates monetizing its new plant lines and existing intellectual property in the second half of 2021, signaling multiple revenue streams ahead.
FAQ
What is the current stock price of 22nd Century Group (XXII)?
What is the market cap of 22nd Century Group (XXII)?
What is the primary focus of 22nd Century Group, Inc.?
What are the key products offered by 22nd Century Group?
What recent financial milestones has the company achieved?
What strategic initiatives is 22nd Century Group currently undertaking?
What is VLN® and how is it significant?
How does 22nd Century Group utilize its biotechnology capabilities?
What are the financial projections for 22nd Century Group?
How does 22nd Century Group's technology benefit the cannabis sector?
What is the significance of the recent contract manufacturing agreements?
How can investors stay updated on 22nd Century Group's developments?
